Shimizu T, Iijima M, Tanaka Y
Department of Radiation Oncology, Tokyo Metropolitan Komagome Hospital.
Nihon Igaku Hoshasen Gakkai Zasshi. 1995 Dec;55(15):1047-52.
Results of radiotherapy in 21 patients who had been treated for intracranial meningioma from April 1975 to March 1993 at Tokyo Metropolitan Komagome Hospital are presented. All patients were treated with 4 MV X-rays using conventional fractionation. The median tumor dose was 54.4 Gy (range 30 Gy to 70 Gy). Radiotherapy was delivered by conformation technique in 11, parallel opposed field in four and three ports technique in two. Of 21 meningiomas, 13 were histologically malignant and 8 were benign. The median follow-up period was 63 months. Overall survival rate at 5 years was 71% for benign and 63% for malignant meningiomas; the 5-year progression-free survival rates were 25% and 30%, respectively. Eight of 21 patients received 60 Gy or more, and the remaining 13 received less than 60 Gy. The 5-year overall survival rates for these two groups were 43% and 83% (p < 0.05), respectively. Ten of 21 patients were treated with post-operative radiotherapy as initial treatment and eleven of 21 patients were treated with salvage therapy with or without surgical excision for recurrent lesions. The 5-year survival rates and progression-free survival rates of these two groups showed no significant differences. From analysis of the clinical course of the salvage therapy group, radiotherapy may prolong survival time and delay further tumor recurrence. According to the present study, radiotherapy (doses of 55 Gy to 60 Gy) after primary resection and at the time of recurrence are equally effective for prolongation of survival and delay of further tumor recurrence.
本文介绍了1975年4月至1993年3月在东京都驹込医院接受治疗的21例颅内脑膜瘤患者的放疗结果。所有患者均采用4MV X射线进行常规分割放疗。中位肿瘤剂量为54.4Gy(范围30Gy至70Gy)。11例采用适形技术、4例采用平行相对野技术、2例采用三野技术进行放疗。21例脑膜瘤中,13例组织学上为恶性,8例为良性。中位随访期为63个月。良性脑膜瘤5年总生存率为71%,恶性脑膜瘤为63%;5年无进展生存率分别为25%和30%。21例患者中有8例接受了60Gy或更高剂量的放疗,其余13例接受的剂量低于60Gy。这两组的5年总生存率分别为43%和83%(p<0.05)。21例患者中有10例接受术后放疗作为初始治疗,21例患者中有11例接受挽救性治疗,包括对复发病灶进行手术切除或不进行手术切除。这两组的5年生存率和无进展生存率无显著差异。通过对挽救性治疗组临床过程的分析,放疗可能会延长生存时间并延迟肿瘤进一步复发。根据本研究,初次切除后及复发时进行放疗(剂量为55Gy至60Gy)对于延长生存期和延迟肿瘤进一步复发同样有效。